[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340732-105":59,"doc-detail-340732-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","exploring-the-clinicopathological-parameters-of-her2-low-breast-cancers-insights-from-a-retrospective-cohort-study","Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study","","Breast cancer subtyping hinges on HER2 expression, yet HER2-low tumors show low HER2 without amplification and remain less characterized despite distinct therapeutic relevance. A retrospective cohort study evaluated histologically confirmed breast cancer cases from January 2022 to December 2023, collecting clinicopathological variables and re-evaluating HER2 by immunohistochemistry and amplification status, with statistical analysis using SPSS. Findings linked HER2-low status to higher tumor stage, nodal involvement, and hormone receptor patterns, and highlighted subtype-specific pathological differences. The study emphasizes the need for personalized clinical management.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-clinicopathological-parameters-of-her2-low-breast-cancers-insights-from-a-retrospective-cohort-study/340732/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-clinicopathological-parameters-of-her2-low-breast-cancers-insights-from-a-retrospective-cohort-study/340732.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What defines HER2 low breast cancer in this study?","Question",{"text":113,"@type":114},"Tumors were classified as HER2-low based on HER2 staining intensity and the absence of amplification on immunohistochemistry reassessment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which clinicopathological factors were evaluated?",{"text":118,"@type":114},"The study collected age, tumor size, nodal involvement, and hormone receptor status, then performed subtype classification using immunohistochemistry.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main results for HER2 low tumors?",{"text":122,"@type":114},"HER2 low tumors showed significant associations with higher tumor stage and nodal involvement, with additional links to androgen receptor positivity and distinct features among hormone receptor-positive and triple-negative subgroups.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340732,1790503498,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Korean Journal of Clinical Oncology 2024;20:79-83 [https://doi.org/10.14216/kjco.24011](https://doi.org/10.14216/kjco.24011)[ ](https://doi.org/10.14216/kjco.24011)[pISSN 1738-8082](pISSN 1738-8082) ∙ eISSN 2288-4084  \nOriginal Article  \nExploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study  \nSana Ahuja, Adil Aziz Khan, Kiruthikasri G, Sufian Zaheer  \nDepartment of Pathology, Safdarjung Hospital, Vardhman Mahavir Medical College, New Delhi, India  \nPurpose: Breast cancer subtypes are delineated by human epidermal growth factor receptor 2 (HER2) expression, pivotal in treatment selection. HER2-positive tumors typically respond to targeted therapies, whereas HER2-negative tumors lack HER2 overexpression. However, a subset exhibits low HER2 expression without amplification, termed HER2 low breast cancer. Despite being distinct, its clinicopathological characteristics and therapeutic implications remain less understood.  \nMethods: A retrospective cohort study was conducted on histologically confirmed breast cancer cases from January 2022 to December 2023. Clinicopathological data including age, tumor size, nodal involvement, and hormone receptor status were collected. Immunohistochemistry categorized tumors into luminal, triple-negative, and HER2-enriched subtypes. HER2 expression was re-evaluated, classifying tumors into HER2 low and HER2-negative based on staining intensity and amplification status. Statistical analysis was performed using SPSS software.  \nResults: Seventy female patients with breast cancer were included, exhibiting diverse clinicopathological features. HER2 low tumors (40%) were significantly associated with higher tumor stage (P=0.03), nodal involvement (P=0.01), and positive androgen receptor expression (P=0.01). Subgroup analysis revealed HER2 low hormone receptor-positive cases (78.6%) were associated with higher tumor stage (P=0.01) and nodal involvement (P=0.01), while HER2 low triple-negative cases (21.4%) demonstrated distinct characteristics such as higher histological grade (P=0.02).  \nConclusion: This study underscores the complexity of HER2 low breast cancer and its implications for clinical management, emphasizing the need for personalized treatment strategies. It provides insights into the clinicopathological parameters of HER2 low breast cancers, highlighting their diverse characteristics and clinical implications.  \nKeywords: Trastuzumab, Breast neoplasms, Triple negative breast neoplasms, Immunohistochemistry  \nINTRODUCTION  \nIn the intricate landscape of breast cancer subtypes, the role of human epidermal growth factor receptor 2 (HER2) has long been a focal point. Traditionally, tumors either exhibit overexpression or amplification of HER2, defining them as HER2-positive, or they lack such aberrations, categorizing them as HER2-negative. As-  \nReceived: Jun 23, 2024 Revised: Sep 23, 2024 Accepted: Sep 24, 2024  \nCorrespondence to: Sufian Zaheer  \nDepartment of Pathology, Safdarjung Hospital, Vardhman Mahavir Medical College, Ansari Nagar, New Delhi 110029, India  \nTel: +91-9650594818, Fax: +91-9958188632  \n[E-mail:](E-mail: sufianzaheer@gmail.com)[ sufianzaheer@gmail.com](E-mail: sufianzaheer@gmail.com)[ ](E-mail: sufianzaheer@gmail.com)© 2024 Korean Society of Surgical Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0](http://creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nsessing HER2 expression in both early and advanced breast cancer cases holds significant clinical importance, as HER2-targeted therapies have substantially improved the prognosis of patients diagnosed with HER2-positive disease. The evaluation of HER2 expression typically involves immunohistochemistry (IHC","cbCaijnRRoz1TrQW","https://ap.wps.com/l/cbCaijnRRoz1TrQW","pdf",346583,"English","# Introduction\n# Methods\n## Patients\n# Results\n# Conclusion","[{\"question\":\"What defines HER2 low breast cancer in this study?\",\"answer\":\"Tumors were classified as HER2-low based on HER2 staining intensity and the absence of amplification on immunohistochemistry reassessment.\"},{\"question\":\"Which clinicopathological factors were evaluated?\",\"answer\":\"The study collected age, tumor size, nodal involvement, and hormone receptor status, then performed subtype classification using immunohistochemistry.\"},{\"question\":\"What were the main results for HER2 low tumors?\",\"answer\":\"HER2 low tumors showed significant associations with higher tumor stage and nodal involvement, with additional links to androgen receptor positivity and distinct features among hormone receptor-positive and triple-negative subgroups.\"}]","Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study | PDF",1790038535,13,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58e341bab1c2d315cc68e688408cb22c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/837fdc4cd584ad57f95776ca26a5e8c5.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9064dc9b1f4626a8547d829d6cbbc60f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dc2617603139f2ff6364ebfb14389fd.webp",980,1306]